KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from ...
Q1 Earnings Forecast for Alumis Issued By Leerink Partnrs
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Alumis in a report released on Sunday, March 23rd. Leerink Partnrs analyst T. Smith forecasts that ...